Medicare

Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer

Staff June 2, 2023

New data emphasizes the value of MRD testing in predicting survival outcomes and informing the personalized treatment of patients with...

Exagen Inc. to Participate in the William Blair 43rd Annual Growth Stock Conference

Staff May 30, 2023

SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its...

Data Presented at the 2023 American Academy of Dental Sleep Medicine and the American Thoracic Society Meetings Further Validate ProSomnus Precision Oral Appliance Therapy for the Treatment of Obstructive Sleep Apnea

Staff May 30, 2023

PLEASANTON, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a leading CPAP alternative for the...

Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma

Staff May 26, 2023

71% objective response rate, with 59% of patients achieving a very good partial response or better at the recommended 200...

Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations

Staff May 26, 2023

Data demonstrate objective response rates from 56% to 63% across three independent cohorts of advanced melanoma patients – about double...

BrainsWay Announces Appointment of Ido Marom as CFO

Staff May 23, 2023

BURLINGTON, Mass. and JERUSALEM, May 23, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...

BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study

Staff May 23, 2023

SUNNYVALE, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. , a developer of cellular and cell-derived therapeutics for the treatment...

iCAD’s ProFound AI Breast Suite Wins U.S. General Services Administration’s AI Healthcare Challenge Award

Staff May 18, 2023

Company presented portfolio of breast cancer detection, density assessment and risk evaluation solutions at the competition, focused on improving health...

BrainsWay Reports First Quarter 2023 Financial Results and Operational Highlights

Staff May 17, 2023

BURLINGTON, Mass. and JERUSALEM, May 17, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...

ReWalk Robotics Reports First Quarter 2023 Financial Results

Staff May 11, 2023

On-Track Start to Fiscal Year with Progress in Advancing Reimbursement Coverage for Medicare Beneficiaries MARLBOROUGH, Mass. BERLIN and YOKNEAM ILLIT, Israel,...

New Long-Term Real-World Research Confirms Xoft Skin eBx is as Safe and Effective as Mohs Surgery

Staff May 11, 2023

98.9% of patients treated with Xoft remained recurrence-free at a median follow-up of 7.6 years, according to recent study published...

Neuronetics Reports Record First Quarter 2023 Financial and Operating Results

Staff May 9, 2023

MALVERN, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “company” or Neuronetics”) a commercial stage medical technology...

Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update

Staff May 4, 2023

Q1 2023 total revenues of $95.3 million, compared to $35.0 million in the same period in 2022 CAPLYTA Q1 2023...

Avertix, Maker of First and Only FDA-Approved Implantable Heart Attack Warning System, to Become Publicly Traded via Merger with BIOS Acquisition Corporation

Staff May 3, 2023

- Transaction values Avertix at an enterprise value of $195 million- Avertix developed the Guardian™ System, the first and only...

Medicare

Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer

Exagen Inc. to Participate in the William Blair 43rd Annual Growth Stock Conference

Data Presented at the 2023 American Academy of Dental Sleep Medicine and the American Thoracic Society Meetings Further Validate ProSomnus Precision Oral Appliance Therapy for the Treatment of Obstructive Sleep Apnea

Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma

Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations

BrainsWay Announces Appointment of Ido Marom as CFO

BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study

iCAD’s ProFound AI Breast Suite Wins U.S. General Services Administration’s AI Healthcare Challenge Award

BrainsWay Reports First Quarter 2023 Financial Results and Operational Highlights

ReWalk Robotics Reports First Quarter 2023 Financial Results

New Long-Term Real-World Research Confirms Xoft Skin eBx is as Safe and Effective as Mohs Surgery

Neuronetics Reports Record First Quarter 2023 Financial and Operating Results

Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update

Avertix, Maker of First and Only FDA-Approved Implantable Heart Attack Warning System, to Become Publicly Traded via Merger with BIOS Acquisition Corporation

Nanox.ARC Imaging System Receives FDA Clearance, Pioneering a New Era in Medical Imaging

Acer Therapeutics Announces OLPRUVA™ Commercial Launch Progressing Ahead of Schedule

Final Sanction Removed at InnovAge Sacramento PACE Center Enabling New Participant Enrollment

iCAD to Report First Quarter 2023 Financial Results on May 15, 2023

TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

Neuronetics Announces Expanded TMS Access through United HealthCare

Hankyung.com introduces: MecKare, Leading the AI-powered Innovation in Health Monitoring Solution

Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

Redefining the Standard of Care: Introducing the Aulisa® Monitor Camera for Advanced Patient Monitoring

Fitness App Market to Expand by USD 55.86 Billion (2024-2028), Driven by Health Management and Rising Chronic Disease Cases, AI Impacting Market Trends – Technavio

Defence Announces Closing of Securities for Debenture Financing

You may have missed